Beyond Sugar

A US clinical-stage biopharmaceutical company has patented a family of novel compounds that inhibit aldose reductase – an enzyme that drives a cascade of harmful cellular changes linked to diabetes complications, cardiovascular disease, kidney disorders, cancer and skin ageing. The invention offers a potential new class of therapeutics capable of addressing multiple serious disease conditions through a single molecular mechanism.

The Problem

Aldose reductase is an enzyme present in many tissues of the body that converts glucose into sorbitol through what is called the polyol pathway. Under normal blood glucose levels, this pathway is relatively inactive. But when blood sugar is elevated – as in diabetes – aldose reductase becomes overactive, generating excess sorbitol and depleting a key cellular antioxidant called NADPH. This sets off a cascade of harmful downstream effects: oxidative stress, cellular damage, impaired vascular function and inflammation.

The consequences of this pathway being chronically overactivated are far-reaching. Diabetic complications including nephropathy (kidney damage), neuropathy (nerve damage), retinopathy (eye damage) and cardiomyopathy are all linked to aldose reductase overactivity. The enzyme also plays a role in ischaemic injury (damage from restricted blood flow), myocardial infarction, atherosclerosis and angiogenesis – the abnormal blood vessel growth associated with certain cancers.

Beyond metabolic and cardiovascular disease, aldose reductase activity contributes to skin ageing and skin disorders through its effects on cellular redox balance and tissue homeostasis. Despite decades of interest in aldose reductase inhibition as a therapeutic strategy, developing compounds with the right combination of potency, selectivity and pharmacological properties has proved challenging.

What This Invention Does

Applied Therapeutics describes a series of novel small molecules falling within the thienopyrimidine and pyrrolopyrimidine chemical classes (reflected in the IPC codes C07D 495/04 and C07D 487/04) – that inhibit aldose reductase activity. These compounds are designed to block the enzyme’s conversion of glucose to sorbitol, cutting off the harmful downstream effects of polyol pathway overactivation.

The patent covers the compounds themselves, their pharmaceutical compositions and a wide range of therapeutic applications: promoting healthy skin ageing, treating skin disorders, treating cardiovascular conditions including coronary artery disease and cardiomyopathy, addressing renal disorders including diabetic nephropathy, managing ischaemic injury, treating evolving myocardial infarction, and addressing angiogenesis-related disorders including certain cancers. The breadth of claimed indications reflects the fundamental role that aldose reductase overactivation plays across multiple disease pathologies.

Key Features

Targeted aldose reductase inhibition. The compounds specifically inhibit aldose reductase, blocking the polyol pathway that drives cellular damage in diabetes complications and other conditions – addressing the root enzymatic mechanism rather than individual downstream effects.

Novel chemical scaffolds. The thienopyrimidine and pyrrolopyrimidine structural classes represent new chemical territory in aldose reductase inhibition, potentially offering improved pharmacological properties compared to earlier inhibitor generations.

Multi-indication therapeutic scope. The same molecular mechanism underlies multiple disease conditions, and the patent claims cover a correspondingly broad range of therapeutic applications – from cardiovascular disease and kidney disorders to cancer and skin conditions.

Diabetes complication coverage. The specification explicitly covers diabetic nephropathy, neuropathy, retinopathy and cardiomyopathy – the major complications that cause most of the morbidity and mortality associated with long-term diabetes.

Dermatological applications. Coverage of skin ageing and skin disorders reflects the role of oxidative stress and aldose reductase in cutaneous tissue health, extending the potential market beyond purely internal disease indications.

Who Is Behind It?

Applied Therapeutics Inc. is a New York-based clinical-stage biopharmaceutical company with a focus on rare diseases and metabolism. The inventor is Andrew Wasmuth. This application is a divisional of AU 2020254610. The application is managed by Davies Collison Cave Pty Ltd in Milton, Queensland.

Why It Matters

The global burden of diabetes and its complications is one of the defining healthcare challenges of the 21st century. Despite advances in glucose management, diabetic complications remain a leading cause of kidney failure, blindness, amputations and cardiovascular death. Therapeutic strategies that address the cellular mechanisms underlying these complications – rather than just managing blood glucose – have enormous clinical potential.

Applied Therapeutics has been building a portfolio of aldose reductase inhibitor programmes targeting specific rare and common conditions. A novel compound series with improved properties could reinvigorate a therapeutic approach that has historically promised more than it has delivered, opening new treatment options for patients with conditions as diverse as heart failure, diabetic kidney disease and cancer. With IPC classifications covering heterocyclic chemistry (C07D 495/04, C07D 487/04), pharmaceutical formulation (A61K 31/5025) and cardiovascular therapeutics (A61P 9/10), the patent spans chemistry through to clinical application.

---

AU 2026201533 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.

Related Concepts

The polyol pathway, driven by aldose reductase, converts excess glucose to sorbitol under hyperglycaemic conditions – a process linked to oxidative stress and microvascular damage in diabetes. Inhibiting this enzyme has long been considered a potential strategy for preventing diabetic complications.

Despite decades of research into aldose reductase inhibitors, translating promising preclinical results into clinical success has proved difficult. Novel chemical scaffolds such as thienopyrimidines may offer improved selectivity and pharmacological properties compared to earlier generations of inhibitors, potentially reinvigorating this therapeutic approach for conditions including diabetic nephropathy and retinopathy.